Survival curves showing therapeutic efficacy of 22-20 and 20-22 in a disseminated Burkitt lymphoma xenograft model. Female C.B. 17 SCID mice were administered 1.5 × 107 Daudi cells intravenously on day 0. (A) Therapy began on day 1 with groups of 6 mice receiving a single intraperitoneal injection (10 pmol) of 22-20, 20-22, v-mab, 22-22, 22-14, 20-14, or saline. (B) Groups of 10 mice were administered 10-μg doses of 22-20, 734-20, 22-14, or 10 μg of both 734-20 and 22-14 on days 1, 4, and 7. Additional groups received 4 μg of e-mab or saline. (C) Groups of 5 NK-cell/neutrophil-depleted or -nondepleted mice were administered intravenous injections of 230 μg of either 22-20 or 20-22 on days 1, 3, 5, and 9. Saline or 100 μg e-mab was administered to nondepleted mice.
